SUNNYVALE, Calif., Oct. 30 Accuray Incorporated(Nasdaq: ARAY), a global leader in the field of radiosurgery, announced todaythat the company has entered into a partnership with Still River Systems,developer of high quality, cost-effective proton beam radiotherapy solutions,and will provide them with a robotic patient positioning system.
Accuray will supply a version of its RoboCouch(R) Robotic PatientPositioning System, which intelligently positions patients with 6 degrees offreedom for treatment, enabling clinicians to automatically re-position thepatient from the control room. The patient positioning system will be usedwith Still River Systems' Monarch 250(TM) PBRT System, a practical, cost-efficient, single-room proton beam radiotherapy (PBRT) system scaled for useat most cancer centers.
"We are pleased that Still River Systems recognizes Accuray's prominentposition in the field of medical robotics and has chosen us to develop theirpatient positioning system," said Chris Raanes, senior vice president andchief operating officer of Accuray Incorporated. "Accuray's technologies areprecise and will allow the Monarch 250 System to provide optimal patientpositioning accuracy and comfort."
"As it is well recognized that precise positioning is required to gain theadvantages of proton therapy, we are excited to work with Accuray to bring newstandards of excellence to positioning patients for these treatments," saidMarc Buntaine, CEO of Still River Systems. "With our Monarch 250 Systemincluding a custom version of the RoboCouch, physicians will be able toquickly and precisely position patients in correct translation and rotationalalignment for each proton treatment fraction."
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is aglobal leader in the field of radiosurgery dedicated to providing an improvedquality of life and a non-surgical treatment option for those diagnosed withcancer. Accuray develops and markets the CyberKnife Robotic RadiosurgerySystem, which extends the benefits of radiosurgery to include extracranialtumors, including those in the spine, lung, prostate, liver and pancreas. Todate, the CyberKnife System has been used to treat more than 35,000 patientsworldwide and currently more than 100 systems have been installed in leadinghospitals in the Americas, Europe and Asia. For more information, please visitwww.accuray.com.
About Still River Systems
Still River Systems, Inc., a company based in Littleton, Massachusetts, isdeveloping the Monarch250 System, a medical device for the treatment of cancerpatients using proton beam radiotherapy (PBRT). The Monarch250 PBRT System isnot FDA cleared.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involverisks and uncertainties, including uncertainties associated with the medicaldevice industry. Except for the historical information contained herein, thematters set forth in this press release regarding procedure growth and marketacceptance, clinical studies, regulatory review and approval, andcommercialization of products are forward-looking statements within themeaning of the "safe harbor" provisions of the Private Securities LitigationReform Act of 1995. Forward-looking statements speak only as of the date thestatements are made and are based on information available at the time thosestatements are made and/or management's good faith belief as of that time withrespect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance andresults to differ materially from the forward-looking statements we makeinclude: market acceptance of products; competing products; need foradditional long-term clinical data; the combination of our products withcomplementary technology; and other risks detailed from